Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

March 31, 2022

Study Completion Date

April 28, 2022

Conditions
Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease
Interventions
DRUG

PF-06865571

Tablet

DRUG

PF-05221304

Tablet

DRUG

Placebo

Tablet

Trial Locations (20)

23294

National Clinical Research, Inc., Richmond

33016

Floridian Clinical Research, LLC, Miami Lakes

33125

Optimus U Corporation, Miami

33434

Excel Medical Clinical Trials, Boca Raton

40213

L-MARC Research Center, Louisville

45219

The Christ Hospital, Cincinnati

45246

Sterling Research Group, Ltd., Cincinnati

78229

Clinical Trials of Texas, Inc., San Antonio

91763

Catalina Research Institute, LLC, Montclair

95648

Clinical Trials Research, Lincoln

96814

East-West Medical Research Institute, Honolulu

B3H 1V7

Nova Scotia Health Authority QE II Health Sciences Centre, Halifax

B3H 2Y9

Nova Scotia Health Authority QE II Health Sciences Centre, Halifax

B3K 4N1

Nova Scotia Health Authority - Queen Elizabeth II Health Sciences Centre, Halifax

L6T 0G1

Aggarwal and Associates Limited, Brampton

N5W 6A2

Milestone Research Inc., London

G7H 4J1

Resonance Magnetique du Saguenay-Lac-Saint-Jean, Chicoutimi

G7H 7K9

Ecogene-21, Chicoutimi

G2J 0C4

Alpha Recherche Clinique, Québec

G1W 4R4

Centre de Recherche Saint-Louis, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY